GHSI.OQ
Latest Trade
1.86USDChange
-0.26(-12.26%)Volume
113,087Today's Range
-
2.0752 Week Range
-
8.34As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 2.12 |
|---|---|
Open | 2.07 |
Volume | 113,087 |
3M AVG Volume | 77.56 |
Today's High | 2.07 |
Today's Low | 1.84 |
52 Week High | 8.34 |
52 Week Low | 0.99 |
Shares Out (MIL) | 24.43 |
Market Cap (MIL) | 51.79 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Guardion Health Regains Compliance With Nasdaq Minimum Bid Price Rule
Guardion Health Sciences - Malaysia's Hwgb Advised Co That Astramern Astra H Granted Product Registration Approval By Malaysian Npra
Guardion Health Sciences Appoints Bret Scholtes As President And CEO
Guardion Health Sciences, Inc. is a health sciences company. The Company operates through two segments: Medical Foods and Vision Testing Diagnostics. Medical Foods segment develops, formulates and distributes condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z that replenishes and restores the macular protective pigment. It has also developed a technology, the MapcatSF, which measures the macular pigment optical density (MPOD). It also provides GlaucoCetin, which is the vision-specific medical food designed to support and protect the mitochondrial function of optic nerve cells and improves blood flow in the ophthalmic artery in patients with glaucoma. The Company’s Vision Testing Diagnostics segment operates under the brand name VectorVision. It specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity and early treatment diabetic retinopathy study (ETDRS) visual acuity testing.
Industry
Biotechnology & Drugs
Contact Info
15150 Avenue of Science Ste 200
SAN DIEGO, CA
92128-3416
United States
+1.858.6059055
http://guardionhealth.com/Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 27.40 |
Price To Book (MRQ) | 3.78 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -80.66 |
Return on Equity (TTM) | -75.40 |
* GUARDION HEALTH SCIENCES ANNOUNCES SUBMISSION OF PATENT APPLICATION FOR TREATMENT OF CERTAIN UNDERLYING CONDITIONS RELATED TO EYE DISEASE Source text for Eikon: Further company coverage:
* GUARDION HEALTH SCIENCES NAMES DR. DAVID EVANS AS INTERIM PRESIDENT AND INTERIM CHIEF EXECUTIVE OFFICER
* GUARDION HEALTH SCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* LUMEGA-Z® DEMONSTRATES SUPERIORITY IN A HEAD-TO-HEAD STUDY SHOWING BETTER BIOAVAILABILITY OF CAROTENOIDS AND RESTORING MACULAR PIGMENT DENSITY
* GUARDION HEALTH SCIENCES - CO'S IMMUNO-SUPPORTIVE/ANTI-OXIDANT COMPLEX ACUMMUNE IS NOW COMMERCIALLY AVAILABLE FOR SALE IN U.S. THROUGH ONLINE PLATFORMS Source text for Eikon: Further company coverage:
* GUARDION HEALTH SCIENCES INC - RECEIVED AN INITIAL PURCHASE FROM ASTRAMUNE SDN BHD FOR A SAMPLE ORDER OF ITS PROPRIETARY IMMUNO-SUPPORTIVE FORMULA Source: https://bit.ly/3aAqcul Further company coverage:
* GUARDION HEALTH SCIENCES GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH BID PRICE RULE Source text for Eikon: Further company coverage:
* GUARDION HEALTH SCIENCES RECEIVES $3.5 MILLION FROM EXERCISE OF WARRANTS Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.